In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
Following the launch of TASECTAN® AF in Denmark in August, Pharmaforce has just marketed this product also in Finland (September) and Sweden (October).
Last April, Noventure granted Pharmaforce exclusive distribution right for TASECTAN® AF in the Nordic markets.
TASECTAN® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different aetiologies in adults and children.
TASECTAN® AF is a class IIa medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments (CE 0476, Noventure SL).
For more information about our products click here: http://noventure.com/products
Noventure grants Pharmaforce exclusive distribution right for its product Tasectan® AF in the countries Denmark, Sweden, Finland, and Norway. Tasectan® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different etiologies in adults and children.
We are pleased to announce the publication of a case series referring about the benefits of Utipro® Plus in some challenging cases of urinary infections. In this new publication, that is the result of a fruitful collaboration among KOLs of international relevance, the product has proved its usefulness as a non-pharmacological approach in recurrent UTIs, thus allowing a rational use of antibiotics.